Mrs Dana Schelegle, LMFTA | |
Po Box 365, Bayboro, NC 28515-0365 | |
(252) 745-4510 | |
Not Available |
Full Name | Mrs Dana Schelegle |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | Po Box 365, Bayboro, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912426164 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 11093A (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Dana Schelegle, LMFTA Po Box 365, Bayboro, NC 28515-0365 Ph: (252) 745-4510 | Mrs Dana Schelegle, LMFTA Po Box 365, Bayboro, NC 28515-0365 Ph: (252) 745-4510 |
News Archive
Congressional Democrats seeking leadership are feeling Sen. Edward Kennedy's absence in the looming health care reform debate as he continues his battle with brain cancer, and struggles to return to Washington, The New York Times reports.
In advance of a United Nations conference today on the global challenges of treating cancer and other diseases, the UBC Graduate School of Journalism has launched an ambitious multimedia site, The Pain Project, which documents one of the greatest challenges to treating chronic illnesses: severely constrained access to morphine.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights to use PlGF for the diagnosis of pre-eclampsia or eclampsia. Clinical trials have shown that PlGF supports the diagnosis and risk prediction for preeclampsia.
› Verified 8 days ago